Article Information
History
- October 1, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Iris Lindberg1,*,#,
- Zhan Shu2,#,
- Hoa Lam2,#,
- Michael Helwig3,
- Nur Yucer4,
- Alexander Laperle4,
- Clive Svendsen4,
- Donato A. Di Monte3 and
- Nigel T. Maidment2,*
- 1University of Maryland-Baltimore
- 2University of California-Los Angeles
- 3German Center for Neurodegenerative Disease (DZNE)
- 4Cedars-Sinai Medical Center, Los Angeles
- ↵*To whom correspondence should be addressed: Iris Lindberg, Ph.D., Department of Anatomy and Neurobiology, University of Maryland Medical School, University of Maryland-Baltimore, Baltimore, MD 21201, Phone: (410) 7064778, Email: ilindberg{at}som.umaryland.edu and Nigel T. Maidment, Ph.D., Department of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles, Los Angeles CA 90024, Phone: (310) 206-7767, Email: nmaidmen{at}ucla.edu
↵# These authors contributed equally
Posted October 01, 2021.
The proSAAS chaperone provides neuroprotection and attenuates transsynaptic α–synuclein spread in rodent models of Parkinson’s disease
